News & Updates

Abrocitinib effectively controls AD regardless of dosing regimen

03 Aug 2023 by

In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.

Abrocitinib effectively controls AD regardless of dosing regimen

03 Aug 2023

Dupilumab confers benefit in bullous pemphigoid

02 Aug 2023 by

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

Dupilumab confers benefit in bullous pemphigoid

02 Aug 2023

Original New Drug Application Approvals by US FDA (16-31 July 2023)

02 Aug 2023

New drug applications approved by US FDA as of 16-31 July 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2023)

02 Aug 2023

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

01 Aug 2023 by

Treatment with JNJ-77242113, an oral interleukin-23 receptor (IL-23R) antagonist peptide, leads to significant improvement in skin lesions, as measured by the Psoriasis Area and Severity Index (PASI) scores, in patients with moderate-to-severe plaque psoriasis, according to the FRONTIER 1 study presented at WCD 2023.

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

01 Aug 2023

Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata

28 Jul 2023 by

An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).

Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata

28 Jul 2023

Nemolizumab relieves itch, clears skin in patients with prurigo nodularis

27 Jul 2023 by

Treatment with nemolizumab significantly improves itch and skin clearance in patients with prurigo nodularis compared with placebo, according to the phase III OLYMPIA 2 trial presented at WCD 2023.

Nemolizumab relieves itch, clears skin in patients with prurigo nodularis

27 Jul 2023

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

In patients with cutaneous squamous cell carcinoma (cSCC) presenting with satellitosis or in-transit metastasis (S-ITM), the size and the number of S-ITM lesions are associated with a higher risk of relapse, while the number of S-ITM confers an increased risk of specific death, reveals a study.

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

A new lotion formulation of 20% oxybutynin hydrochloride (20% OL) demonstrates efficacy in reducing palmar sweat volume among patients with primary palmar hyperhidrosis (PPHH) when compared with placebo, results of a phase III study have shown.

Novel lotion formulation helps reduce palm sweating

18 Jul 2023

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Treatment of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer with high mortality and rising incidence, at either an academic or a high-volume centre tends to lead to better patient survival, as shown in a recent study.

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis

14 Jul 2023 by

Asian patients with moderate to severe plaque psoriasis may benefit from ustekinumab therapy, which has been shown to be both safe and effective in a Singapore study.

Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis

14 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Abrocitinib effectively controls AD regardless of dosing regimen

Abrocitinib effectively controls AD regardless of dosing regimen

Dupilumab confers benefit in bullous pemphigoid

Dupilumab confers benefit in bullous pemphigoid

Original New Drug Application Approvals by US FDA (16-31 July 2023)

Original New Drug Application Approvals by US FDA (16-31 July 2023)

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata

Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata

Nemolizumab relieves itch, clears skin in patients with prurigo nodularis

Nemolizumab relieves itch, clears skin in patients with prurigo nodularis

S-ITM lesions predict relapse in cutaneous SCC

S-ITM lesions predict relapse in cutaneous SCC

Novel lotion formulation helps reduce palm sweating

Novel lotion formulation helps reduce palm sweating

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis

Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis